The same analysis in RB654 organoids showed significant reductions in the proportion of proliferative tumor cones (RXRG+ Ki67+: RXRG+) following treatment with sunitinib (42.74% ± 2.72%) and topotecan (51.92% ± 1.28%) but no significant change with melphalan treatment (57.07% ± 1.71%) compared with vehicle (59.03% ± 1.79%) (Fig. 5I–M). This evidence concerns the gene RXRG and neoplasm.